文献速递肥胖与代谢综合征

AICAR改善高脂饮食相关病理生理,不依赖脂联素:小鼠及离体模型研究

AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin.
PubMed 文献 · Diabetologia · 2017-02-10

研究评估AMPK激活剂AICAR对高脂饮食诱导小鼠病理生理的治疗潜力及是否依赖脂联素,并用肥胖者脂肪组织离体验证。AICAR减轻脂肪炎症、促进M1向M2巨噬细胞表型转换、减少CD8+ T细胞浸润,部分恢复糖耐量并减轻肝脂肪变和肾病,且在野生型和Adipoq-/-小鼠中保护相似,不依赖脂联素;人脂肪组织离体也显示抗炎作用。

要点

  • AICAR减轻高脂饮食小鼠脂肪炎症,促进M1向M2巨噬细胞表型转换并减少CD8+ T细胞浸润。
  • AICAR部分恢复糖耐量并减轻肝脂肪变和肾病,野生型与Adipoq-/-小鼠保护相似,不依赖脂联素。
  • 肥胖者脂肪组织离体经AICAR处理促进M1向M2转换并减少TNF-α产生。

核心结论

  • AICAR可能以不依赖脂联素的方式促进代谢健康并预防肥胖诱导的系统性疾病,人脂肪组织离体结果提示其可能减少肥胖相关并发症。

研究设计与样本

  • 6周龄雄性C57BL/6J野生型和Adipoq-/-小鼠喂饲标准脂肪饮食(10%脂肪)或高脂饮食(60%脂肪)12周,第4–12周每周三次给予溶媒或AICAR(500 μg/g)。
  • 第11周行IPGTT,第12周行流式细胞术和蛋白质印迹检测饮食诱导的病理生理。
  • 肥胖(BMI 35–50 kg/m2)个体脂肪组织活检标本在37°C下与溶媒或AICAR(1 mmol/l)孵育6小时,以ELISA(TNF-α)和流式细胞术表征炎症。

主要发现

  • AICAR减轻高脂饮食小鼠脂肪炎症,促进M1向M2巨噬细胞表型转换,同时减少CD8+ T细胞浸润。
  • AICAR部分恢复高脂饮食小鼠糖耐量,并减轻肝脂肪变和肾病,表现为野生型和Adipoq-/-小鼠白蛋白尿(p < 0.05)、尿H2O2(p < 0.05)和肾脏超氧化物水平(p < 0.01)降低。
  • AICAR介导的保护不依赖脂联素,因野生型和Adipoq-/-小鼠观察到相似保护。
  • AICAR促进肥胖人患者组织外植体M1向M2巨噬细胞表型转换并减少TNF-α产生。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In this study, we aimed to evaluate the therapeutic potential of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), an activator of AMP-activated protein kinase, for ameliorating high-fat diet (HFD)-induced pathophysiology in mice. We also aimed to determine whether the beneficial effects of AICAR were dependent on adiponectin. Furthermore, human adipose tissue was used to examine the effect of AICAR ex vivo. METHODS: Six-week-old male C57BL/6J wild-type and Adipoq -/- mice were fed a standard-fat diet (10% fat) or an HFD (60% fat) for 12 weeks and given vehicle or AICAR (500 μg/g) three times/week from weeks 4-12. Diet-induced pathophysiology was examined in mice after 11 weeks by IPGTT and after 12 weeks by flow cytometry and western blotting. Human adipose tissue biopsies from obese (BMI 35-50 kg/m2) individuals were incubated with vehicle or AICAR (1 mmol/l) for 6 h at 37°C, after which inflammation was characterised by ELISA (TNF-α) and flow cytometry. RESULTS: AICAR attenuated adipose inflammation in mice fed an HFD, promoting an M1-to-M2 macrophage phenotype switch, while reducing infiltration of CD8+ T cells. AICAR treatment of mice fed an HFD partially restored glucose tolerance and attenuated hepatic steatosis and kidney disease, as evidenced by reduced albuminuria (p < 0.05), urinary H2O2 (p < 0.05) and renal superoxide levels (p < 0.01) in both wild-type and Adipoq -/- mice. AICAR-mediated protection occurred independently of adiponectin, as similar protection was observed in wild-type and Adipoq -/- mice. In addition, AICAR promoted an M1-to-M2 macrophage phenotype switch and reduced TNF-α production in tissue explants from obese human patients. CONCLUSIONS/INTERPRETATION: AICAR may promote metabolic health and protect against obesity-induced systemic diseases in an adiponectin-independent manner. Furthermore, AICAR reduced inflammation in human adipose tissue explants, suggesting by proof-of-principle that the drug may reduce obesity-induced complications in humans. TRIAL REGISTRATION: ClinicalTrials.gov NCT02322073.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Börgeson E, Wallenius V, Syed GH, et al. AICAR ameliorates high-fat diet-associated pathophysiology in mouse and ex vivo models, independent of adiponectin. Diabetologia. 2017. PMID: 28188334. doi:10.1007/s00125-017-4211-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。